Stifel Reiterates Buy Rating on Fate Therapeutics (FATE) Ahead of FT596 Readout
Tweet Send to a Friend
Stifel analyst Benjamin Burnett reiterated a Buy rating and $116.00 price target on Fate Therapeutics (NASDAQ: FATE) ahead of the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
